Optimizing levofloxacin delivery using nanoparticles: a strategy for improved bioavailability and targeted release
Abstract
Nanoparticle-based drug delivery systems have emerged as a powerful strategy to enhance drug bioavailability and ensure targeted therapeutic release. Levofloxacin (LFX), a widely used broad-spectrum fluoroquinolone antibiotic, is limited by poor aqueous solubility, low oral bioavailability, and systemic side effects. This study investigates the formulation, characterization, and evaluation of levofloxacin-loaded nanoparticles aimed at improving its pharmacological performance. Various nanoparticle carriers, including polymeric nanoparticles, lipid-based nanocarriers, and inorganic nanoparticles, were explored for their ability to encapsulate LFX and improve its delivery. Key formulation parameters such as encapsulation efficiency, drug loading, in vitro release profile, and stability at 4°C, 25°C, and 40°C were assessed. The optimized formulations demonstrated acceptable stability and sustained drug release across the tested conditions. Biocompatibility studies revealed no significant cytotoxic effects, as confirmed by high cell viability percentages, indicating the safety of the nanoparticle systems. Furthermore, the nanoparticle-loaded formulations exhibited enhanced dissolution behavior and potent in vitro antimicrobial activity against both Gram-negative and Gram-positive bacteria (p<0.05). Pharmacokinetic studies revealed statistically significant improvements (p<0.05) in maximum plasma concentration (Cmax), elimination half-life (t1/2), and area under the curve (AUC)…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.